4 Stocks Pushing The Diversified Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 24 points (-0.2%) at 14,029 as of Friday, March 1, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,249 issues advancing vs. 1,609 declining with 131 unchanged.

The Diversified Services industry currently is unchanged today versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include American Public Education ( APEI), down 7.8%, Corrections Corporation of America ( CXW), down 3.2%, Rollins ( ROL), down 2.3%, Alliance Data Systems Corporation ( ADS), down 0.9% and Fiserv ( FISV), down 0.8%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Qiagen ( QGEN) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Qiagen is down $0.25 (-1.2%) to $21.19 on light volume Thus far, 272,534 shares of Qiagen exchanged hands as compared to its average daily volume of 845,400 shares. The stock has ranged in price between $21.04-$21.25 after having opened the day at $21.17 as compared to the previous trading day's close of $21.44.

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. Qiagen has a market cap of $5.0 billion and is part of the services sector. The company has a P/E ratio of 46.4, above the S&P 500 P/E ratio of 17.7. Shares are up 17.6% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Qiagen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Qiagen as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Qiagen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

3 Diversified Services Stocks Nudging The Industry Higher

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Watch Out: Barbarians At The Gate For Qiagen (QGEN)